The US Food and Drug Administration (FDA) said on Friday that it has granted marketing approval to Pfizer Inc.’s acute migraine drug Relpax (eletriptan). The drug has won US clearance for 20-mg and 40-mg tablets, according to a notice from the agency.
Pfizer received approval this summer to market Relpax in all member nations of the European Union in 20-mg, 40-mg and 80-mg tablets, with the UK serving as the reference member state. The drug is also sold in Japan.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!